

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kayyem Jon Faiz</u>			2. Issuer Name and Ticker or Trading Symbol <u>BIODESIX INC [ BDSX ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>12/06/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>2970 WILDERNESS PLACE SUITE 100</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>BOULDER CO 80301</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(1)	12/06/2021		A		31,619		(2)	(2)	Common Stock	31,619	\$0	31,619	D	
Stock Options (Right to Buy)	\$5.93	12/06/2021		A		50,368		(3)	12/05/2031	Common Stock	50,368	\$0	50,368	D	
Stock Options (Right to Buy)	\$5.67	12/07/2021		A		27,038		(4)	12/06/2031	Common Stock	27,038	\$0	27,038	D	

**Explanation of Responses:**

- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- These restricted stock units will vest in full on December 6, 2022, generally subject to the reporting person's continued service on the Issuer's board of directors (the "Board") through the applicable vesting date, and have no expiration date.
- This option vests 40% on December 6, 2023, and the remaining 60% in 36 successive, equal monthly installments measured from December 6, 2023, generally subject to the reporting person's continued service on the Board through the applicable vesting date.
- This option will vest in full on March 31, 2022, subject to the reporting person's continued service on the Board through the applicable vesting date. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period.

/s/ Robin H. Cowie as  
Attorney-in-Fact for Jon Faiz 12/08/2021  
Kayyem

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.